Date | Open | Close | Daily High | Daily Low |
---|
Price change over selected period: 0% 0
- All
- Buy
- Hold
- Sell
- Yearly
- Quarterly
2024 | 2025 | 2026 | 2027 | 2028 | |
---|---|---|---|---|---|
Revenue | 3,431 | 3,748 | 4,172 | 4,757 | 5,098 |
Dividend | 0.78 | 0.95 | 1.16 | 1.75 | 1.90 |
Dividend Yield (in %) | 0.31 % | 0.38 % | 0.46 % | 0.69 % | 0.75 % |
EPS | 4.39 | 5.56 | 7.10 | 9.42 | 10.54 |
P/E Ratio | 57.61 | 45.49 | 35.60 | 26.85 | 24.01 |
EBIT | 618 | 759 | 922 | 1,133 | 1,273 |
EBITDA | 973 | 1,126 | 1,311 | 1,513 | 1,622 |
Net Profit | 161 | 263 | 369 | 569 | 629 |
Net Profit Adjusted | 303 | 381 | 501 | 636 | 750 |
Pre-Tax Profit | 440 | 606 | 820 | 1,014 | 1,147 |
Net Profit (Adjusted) | 398 | 584 | 756 | 942 | 990 |
EPS (Non-GAAP) ex. SOE | - | - | - | - | - |
EPS (GAAP) | 2.61 | 4.07 | 5.61 | 7.44 | 8.72 |
Gross Income | 1,629 | 1,817 | 2,051 | 2,302 | 2,523 |
Cash Flow from Investing | 39 | -482 | -532 | -546 | -554 |
Cash Flow from Operations | 785 | 813 | 954 | 1,212 | 1,341 |
Cash Flow from Financing | 39 | -482 | -532 | -546 | -554 |
Cash Flow per Share | 10.61 | 11.61 | 14.05 | 14.63 | 17.57 |
Free Cash Flow | 373 | 450 | 586 | 726 | 820 |
Free Cash Flow per Share | 3.92 | 4.90 | 7.27 | 15.99 | 19.44 |
Book Value per Share | 57.29 | 59.10 | 65.22 | 52.17 | 62.42 |
Net Debt | 4,035 | 3,805 | 3,478 | 3,270 | 2,968 |
Research & Development Exp. | 177 | 183 | 191 | 212 | 235 |
Capital Expenditure | 411 | 382 | 388 | 454 | 456 |
Selling, General & Admin. Exp. | 877 | 906 | 953 | 1,090 | 1,170 |
Shareholder’s Equity | 2,926 | 3,185 | 3,533 | 4,137 | 4,913 |
Total Assets | 10,172 | 10,257 | 10,255 | 10,738 | 11,087 |
Previous Quarter ending 06/30/24 | Current Quarter ending 09/30/24 | Next Quarter ending 12/31/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
---|---|---|---|---|---|
Earnings Estimates | |||||
No. of Analysts | 5 | 5 | 5 | 20 | 20 |
Average Estimate | 1.037 EUR | 1.057 EUR | 1.322 EUR | 4.390 EUR | 5.560 EUR |
Year Ago | 1.389 EUR | 0.126 EUR | 0.123 EUR | 2.999 EUR | - |
Publish Date | 7/18/2024 | 10/17/2024 | 1/23/2025 | - | - |
Revenue Estimates | |||||
No. of Analysts | 5 | 5 | 5 | 20 | 20 |
Average Estimate | 849 EUR | 847 EUR | 884 EUR | 3,431 EUR | 3,748 EUR |
Year Ago | 832 EUR | 811 EUR | 850 EUR | 3,396 EUR | - |
Publish Date | 7/18/2024 | 10/17/2024 | 1/23/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Date | Name | Dividend | *yield | Currency |
---|---|---|---|---|
2023 | Sartorius AG Vz. | 0.74 | 0.22 | EUR |
2022 | Sartorius AG Vz. | 1.44 | 0.39 | EUR |
2021 | Sartorius AG Vz. | 1.26 | 0.21 | EUR |
2020 | Sartorius AG Vz. | 0.71 | 0.21 | EUR |
2019 | Sartorius AG Vz. | 0.36 | 0.19 | EUR |
2018 | Sartorius AG Vz. | 0.62 | 0.57 | EUR |
2017 | Sartorius AG Vz. | 0.51 | 0.64 | EUR |
2016 | Sartorius AG Vz. | 0.46 | 0.65 | EUR |
2015 | Sartorius AG Vz. | 0.38 | 0.63 | EUR |
2014 | Sartorius AG Vz. | 0.27 | 1.07 | EUR |
2013 | Sartorius AG Vz. | 0.26 | 1.18 | EUR |
2012 | Sartorius AG Vz. | 0.24 | 1.43 | EUR |
2011 | Sartorius AG Vz. | 0.21 | 2.31 | EUR |
2010 | Sartorius AG Vz. | 0.16 | 2.26 | EUR |
2009 | Sartorius AG Vz. | 0.11 | 2.64 | EUR |
2008 | Sartorius AG Vz. | 0.11 | 5.15 | EUR |
2007 | Sartorius AG Vz. | 0.17 | 2.52 | EUR |
2006 | Sartorius AG Vz. | 0.16 | 1.94 | EUR |
2005 | Sartorius AG Vz. | 0.13 | 2.54 | EUR |
2004 | Sartorius AG Vz. | 0.11 | 2.76 | EUR |
2003 | Sartorius AG Vz. | 0.07 | 3.94 | EUR |
2002 | Sartorius AG Vz. | 0.07 | 7.03 | EUR |
2001 | Sartorius AG Vz. | 0.07 | 3.71 | EUR |
2000 | Sartorius AG Vz. | 0.07 | 3.02 | EUR |
*Yield of the Respective Date
Sartorius AG engages in the provision of solutions for biopharmaceutical research. It operates through following divisions: Bioprocess Solutions (BPS), and Lab Products and Service (LPS). The Bioprocess Solutions division focuses on single-use solutions, helps customers manufacture biotech medications and vaccines safely and efficiently. The Lab Products and services division serves the needs of laboratories performing research and quality control at pharma and biopharma companies and those of academic research institutes. The company was founded by Florence Sartorius, Sr. in 1870 and is headquartered in Goettingen, Germany.
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’sbalance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of creditrisk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes intoaccount day-to-day movements in market value compared to a company’s liability structure.
Owner | in % |
---|---|
Freefloat | 65.71 |
Bio-Rad Laboratories, Inc. | 25.61 |
Sartorius AG | 8.68 |
Vanguard International Growth Fund | 3.70 |
T Rowe Price Growth Stock Fund | 1.87 |
T Rowe Price New Horizons Fund | 1.74 |
Franklin Growth Fund | 1.27 |
BNP Paribas Funds - Aqua | 1.03 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
Name | Job |
---|---|
Lothar Kappich | Chairman-Supervisory Board |
Joachim Kreuzburg | Chief Executive Officer |
Florian Funck | Chief Financial Officer |
René Fáber | Head-Bioprocess Solutions Division |
Alexandra Gatzemeyer | Head-Lab Products & Services Division |
Volker Niebel | Head-Production, Procurement & Business Operations |
Oscar-Werner Reif | Head-Research & Development |
David Raymond Ebsworth | Member-Supervisory Board |
Dietmar Müller | Member-Supervisory Board |
Klaus Rüdiger Trützschler | Member-Supervisory Board |
Annette Becker | Member-Supervisory Board |
Daniela Favoccia | Member-Supervisory Board |
Hermann Jens Ritzau | Member-Supervisory Board |
Sabrina Wirth | Member-Supervisory Board |
Ilke Hildegard Panzer | Member-Supervisory Board |
Frank Riemensperger | Member-Supervisory Board |
Petra Kirchhoff | Member-Supervisory Board & Head-IR |
Manfred Zaffke | Vice Chairman-Supervisory Board |
ncG1vNJzZmilkae4psDSZ5muq5mjsrS%2FyKeqopyVp3uku8xoqq2nk6DAcL%2FUr6efZaOpvKS3